In human peripheral interstitial fluid, esterification of cholesterol by lecithin cholesterol acyltransferase (LCAT) was found to occur at a rate of only 10% of that in plasma (5.6±1.8 compared with 55.6±7.8 nmol/ml per h). Measurement of cholesterol esterification in the presence of excess reconstituted apoA-I HDL (rA-I HDL) revealed an LCAT activity in interstitial fluid of 24% of that in plasma, indicating that the low rate of esterification could not be caused by limiting mass of LCAT enzyme. When plasma was diluted to the same concentration as in interstitial fluid, the percent cholesterol esterification rate was the same as undiluted plasma and significantly higher than that of interstitial fluid. These findings led us to postulate that poor activation of LCAT in interstitial fluid may result from a change in conformation in apoA-I. To test this hypothesis, a monoclonal antibody Al-11 that inhibits apoA
Introduction
Lecithin cholesterol acyl transferase (LCAT)' is an enzyme that catalyses the fatty acid esterification of cholesterol from cholesterol and phosphatidyl choline ( 1 ) and is responsible for the presence of most of the cholesteryl esters in circulating plasma. As a consequence of this reaction, cholesterol is converted into the more hydrophobic cholesteryl ester. In turn, phosphatidyl choline is changed into lysophosphatidyl choline. 1 . Abbreviations used in this paper: IF/P, interstitial fluid/plasma ratio; LCAT, lecithin cholesterol transferase; rA-I-HDL, reconstituted apoA-I HDL. This causes the cholesterol to transfer from the surface of the lipoprotein into the core (2) . By facilitating this esterification ofcholesterol, LCAT plays a major role in the transfer ofcholesterol from the peripheral tissues to the liver, where essentially all of the cholesterol is metabolized (3) . This enzyme helps to reshape HDL (4, 5) , especially the conversion of discoidal HDL to spherical ones (5) , and together with cholesteryl ester transfer protein, facilitates the redistribution of lipids (cholesterol ester for triacylglycerol) between different lipoprotein classes ( 1).
The important events ofreverse cholesterol transport occur extravascularly; i.e. within the interstitial space. To understand reverse cholesterol transport in the interstitial space, we have chosen to study lipoprotein metabolism in the prenodal peripheral lymph. This is an accepted model for interstitial fluid. During the past decade, our laboratory has been systematically characterizing lipoproteins and apolipoproteins in the peripheral lymph ofdogs (6) (7) (8) (9) (10) . In general, lymph lipoproteins have more HDL relative to LDL and very low density lipoproteins ( 10) . The lipid content and particle size of the lymph lipoproteins are also different from their plasma counterparts. To determine the cause of the differences in lipoprotein lipid content, we have measured the activities of lipoprotein lipase and hepatic triacylglycerol lipase in both the plasma and lymph (11) . Our study indicated that there is virtually no hepatic triacylglycerol lipase activity and very little lipoprotein lipase activity in the periphery ( 11) . This suggests that the differences in lipoprotein composition in lymph could not have resulted from lipase modification.
A large proportion of dog prenodal lymph HDL, especially from animals fed a high cholesterol diet, is discoidal (7) . Since the presence ofthese particles is associated with familial LCAT deficiency ( 12) , it is reasonable to assume that dog lymph contains little LCAT activity. Indeed very little activity was found (9) when LCAT activity was measured using the StokkeNorum assay ( 13).
Our findings using dog lymph as a model are consistent with those published by others using human lymph. A review of the subject has been published recently ( 14) . In this report, we used a suction technique ( 15 ) to isolate human interstitial fluid. We found that human interstitial fluid LCAT activity is lower than expected based on its molecular size and the sieving characteristics ofthe interstitial space. Collection of interstitial fluid. Interstitial fluid was obtained from the scapular region of normal human volunteers using a suction device (Dermovac Instrumentarium, Helsinki, Finland), as described by Kiistala ( 16) . Mild suction (200-250 mmHg) was applied to the skin for 2 h. After this period, the accumulated fluid (0.3-0.6 ml) was withdrawn from the resulting blisters using a syringe equipped with a 25-gauge needle and placed on ice. All fluids were immediately adjusted to 1 mM EDTA, 0.1% Na azide, and analyzed within 24 h.
Lecithin cholesterol acyl transferase assays. The rate of cholesterol esterification was measured using the method of Stokke-Norum ( 13) described previously (8) . These assays were carried out immediately after the collection of suction fluid. Briefly, to 20 LCAT activity was measured based on the method of Jonas et al. (17) , using reconstituted apoA-I high density lipoproteins (rA-I HDL). Reconstituted apoA-I HDLs were prepared using cholate/eggyolk lecithin/unesterified cholesterol/apoA-I in a molar ratio of 100:100:10:1. Interstitial fluid or plasma was incubated at 37°C with rA-I HDL substrate ( 12 Mg cholesterol, 0.04 MCi) and 2-mercaptoethanol (4 mM) in a buffer containing 10 mM Tris, 150 mM NaCl, 0.01% EDTA, 0.8% BSA, pH 7.4. At the indicated times, the reaction was terminated and cholesterol and cholesteryl esters were extracted, separated, and counted as with the rate of cholesterol esterification assay.
LCAT was purified 12,000-fold from blood bank plasma using the method of Bonelli and Jonas ( 18) . Briefly, total lipoproteins were removed from human plasma by ultracentrifugation. The clear middle zone between the lipoprotein and other proteins was used for chromatography on a phenyl-Sepharose column. The pooled fractions with LCAT activity were dialyzed and applied to a DEAE Sephacryl column. The eluate from the ion exchange column containing LCAT activity was pooled, dialyzed, and then subjected to a hydroxylapatite column. The eluate from the hydroxylapatite column was then dialyzed and stored for use ( 17) . Apolipoprotein A-I was purified using a single step gel filtration ofdelipidated HDL3 in reduced (5 mM DTT) 4 M guanidium hydrochloride, 0.1 M Tris-Cl, pH 8.6 buffer using a Sephacryl S-300 column ( 19) .
ELISA. The polyclonal competitive ELISA has been described in detail in another publication (19) . Briefly, HDL (1.063 < d < 1.21 g/ml) was coated onto microtiter plates (Nunc MaxiSorp F96; Vangard International Inc., Neptune, NJ) and incubated at room temperature overnight. Polyclonal antibody and either unknown sample or plasma standard were incubated together in microfuge tubes overnight. This mixture was then introduced into wells of the ELISA plate. The HDL served to capture antibody not complexed to the ligand. This HDL-bound antibody was then localized with peroxidase-linked antibody and quantified by color reaction using a peroxidase substrate.
This assay was not affected by sample deamination, length of sample storage, or sample delipidation ( 19) .
All the monoclonal antibodies used in this paper have been described and characterized previously (20) (21) (22) (23) . To compare the binding of monoclonal antibodies Al-IO and Al-II to apoA-I, two sandwich ELISAs were established. The polyclonal anti apoA-I used in the competitive ELISA was used as a capture agent. This ensured a constant quantity of apoA-I was captured before detection with the different monoclonal antibodies. For these assays, the polyclonal anti-apoA-I IgG was purified by ammonium sulfate precipitation (24) followed by DEAE Sephacryl chromatography (final concentration 30 qg/ml in 0.01 M sodium phosphate, 0.145 M NaCl, pH 7.4 buffer containing 0.1% sodium azide). The microtiter plates were coated with 100 Ml of anti apoA-I IgG at 370C for 2 h. The plates were then washed three times with NaCI/Pi/Tween buffer (0.01 M sodium phosphate, pH 7.4, and 0.145 M NaCl with 0.05% Tween-20), using a plate washer (Skatron Microwash II; Lier, Norway). The remaining binding sites were blocked by adding 150 Mil/well of 1% BSA (Cohn Fraction V, filtered through 0.45-,gm filter) in NaCl/Pi buffer and incubated at 370C for I h. The plates were washed three times with NaCl/Pi/Tween buffer. ApoA-I in plasma and interstitial fluid (diluted sequentially from 3,000-to 30,000-fold with NaCl/Pi/Tween buffer) was then mixed with either the monoclonal antibody Al-10 or AI-1I (ascites fluid, diluted 6,000-fold in NaCI/Pi/Tween) and 100 ul was dispensed per well. The plates were incubated at room temperature (25°C), overnight ( 16-20 h) , and then washed three times with NaCl/Pi/Tween buffer. 100 Ml of peroxidase-labeled rabbit anti-mouse antibody (ICN Biomedicals, Inc., Costa Mesa, CA, or Zymed Labs Inc., South San Francisco, CA) diluted 500-fold with NaCl/Pi buffer containing 1% BSA were pipetted into each well, and the plates were incubated for 1 h at room temperature (25°C). After incubation, the plates were washed, and 100 Mil of color reagent was added to each well. The color reagent contained 1.8 mM ABTS [2',2-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid), 0.003% H202, 0.1 M sodium phosphate buffer, pH 6.0. Optical density was measured using an ELISA plate reader (SLT EAR 400 AT; SLT Lab Instruments, Hillsborough, NC) using a measuring wavelength of 405 nm and reference wavelength of 492 nm. The data was directly imported to an IBM PC-AT compatible microcomputer (Z248; Zenith) and analyzed using software (Immunofit; Beckman Instruments, Inc., Fullerton, CA). The analysis software was based on the four-parameter curve fitting proposed by Rodbard et al (25) . For the sandwich assay using monoclonal antibody AI-I 1, the procedures are identical except NaCl/Pi buffer was used instead of the NaCl/Pi/ Tween buffer in all instances.
Other analytical techniques. Free and total cholesterol determination determinations were done according to the method of McGowan et al (26) . Albumin and apoB concentrations were determined by rocket immunoelectrophoresis (27) . Total protein was determined by the method of Lowry et al (28) .
Results
The composition of human interstitial fluid obtained from the scapular region by negative pressure is summarized in Table I . These data are in agreement with values reported by others using a similar device on the upper arm ( 15) and are consistent with our findings reported for dog peripheral lymph (10) .
An interesting observation made during investigation of dog peripheral lymph was that the ability ofthis fluid to esterify cholesterol was very low (9) . To test whether this also occurs in human subjects, we compared the rate ofcholesterol esterification of plasma and interstitial fluid. As shown in Fig. 1 A, the rate of cholesterol esterification of plasma was considerably higher than interstitial fluid. Because plasma also contained four times more free cholesterol than interstitial fluid ( 1,195 vs 303 nmol/ml), we determined the lowered rate of cholesteryl esterification in interstitial fluid was caused by the lower concentration of substrate lipoproteins. Results showed that plasma, diluted to 1 / 5 of its concentration, still had a higher rate of cholesterol esterification than interstitial fluid (Fig. I  A) . However, when expressed as a percent cholesterol esterified (Fig. 1 B) , plasma diluted to 1/5 of its original gave similar Interstitial fluid was collected from the scapular region as described in Methods. Our interstitial fluid values were similar to those previously reported (15) . Values are mean and SD of six individuals. Values for apolipoproteins and albumin were obtained using rocket immunoelectrophoresis (27) . The mean cholesterol value was 183 mg/dl in the plasma. Fig. 1 A, except that it is expressed as relative rates of cholesterol esterification (percent cholesterol esterified). LCAT activity was measured using the Stokke-Norum assay for interstitial fluid, plasma, and diluted plasma for an individual. This result highlights the observation, illustrated in Fig. 1 A, that interstitial fluid lipoproteins were different from plasma lipoproteins in their ability to activate LCAT. By expressing the data this way, we also demonstrate that the differences observed between plasma and interstitial fluid are not caused by low concentration of free cholesterol in interstitial fluid. By diluting the plasma fivefold, the absolute rate of cholesterol esterification was decreased (Fig. 1 A) , but the relative rate of cholesterol esterification (percent esterified) was unchanged.
percent of esterification as that of undiluted plasma. Thus, esterification in interstitial fluid is lower than would be expected from a simple dilution of plasma.
To test if the reduced rate of esterification in interstitial fluid could be explained by limiting concentrations of LCAT enzyme, we measured LCAT enzyme activity in the plasma and interstitial fluid using rA-I HDLs as substrate ( 17) . Under these conditions, the amount of cholesterol esterified in interstitial fluid increased six-to sevenfold, while that in plasma increased only two-to threefold (Table II) . The interstitial fluid/plasma (IF/P) ratio for LCAT increased from 10%, using the endogenous substrate, to 24% using rA-I HDL, a value similar to IF/P ratio of apoA-I. These data show that the low rate of esterification in interstitial fluid is not a result of low levels of LCAT and indicate that interstitial fluid lipoproteins are poor substrates for LCAT.
Interstitial fluid lipoproteins might possibly be poor substrates for LCAT because of subtle changes in epitope expression of interstitial fluid apoA-I. Therefore, we constructed ELISAs using well defined monoclonal antibodies to probe for differences in the structure and conformation of apoA-I in interstitial fluid vs plasma.
Both monoclonal antibodies, AI-10 and Al-1 1, can be considered pan apoA-I antibodies because they bind 93-100% of plasma apoA-I (20) . Monoclonal antibody AI-1I recognizes amino acids 96-1 1 1 of apoA-I (21 ), a region shown to be important for LCAT activation. The results of the sandwich ELISA using monoclonal antibody AI-10 as a detector antibody are shown in Fig. 2 (Fig. 3) . Furthermore, there was a correlation between the relative affinity of AI-11 (as measured by the slope) for interstitial fluid apoA-I and the levels ofcholesterol esterification in interstitial fluid (Fig. 4) . ln vitro incubations, using monoclonal antibodies Al-10 or AI-I with rA-I HDLs and purified LCAT, showed that binding of AI-I to apoA-I was sufficient to inhibit apoA-I activation of LCAT (21 ) . AI-1 1 or Al-10 was preincubated with rA-I HDLs in a 1: 1 molar ratio of apoA-I to antibody 30 min before the addition of a purified LCAT. The monoclonal antibody AI-lI was able to inhibit LCAT to 19% ofthat in control (Fig. 5  A) , whereas monoclonal antibody Al-10 inhibited LCAT activation to 85% of control. Log Apo A-I (g/ml) by comparing the slope Subjects of the ELISA, shown in Fig. 3 , between the plasma and interstitial fluid. If the slopes were identical, then the relative affinity would be 100%. This value was then paired with the relative rate of cholesterol esterification in a sample from the same subject. Note that with more affinity of AI-l 1 to interstitial fluid apoA-I, there is less inhibition of cholesterol esterification. This correlation is not absolute. Subjects 3 and 4 had the same rate of cholesterol esterification and yet subject 4 had a higher relative affinity, as defined by binding to Al-I 1. n, percent relative affinity; ., percent rate of cholesterol esterification.
When plasma HDL ( 1.063 < d < 1.21 ) was used, monoclonal antibody Al-lI was able to inhibit LCAT to 37% ofcontrol, whereas monoclonal antibody Al-10 inhibited LCAT to 84% of control (Fig. 5 B) . Thus, the degree of LCAT inhibition was similar for AI-10 regardless of substrate but not for AI-1 1.
Discussion
The data presented here show that cholesterol esterification rate is low in interstitial fluid. This finding has been reported previously for human subcutaneous lymph (29, 30) , dog cardiac and thoracic duct lymph (31 ), as well as dog prenodal peripheral lymph (9) . The reason for the low esterification has not been elucidated. We show here that the low esterification rate is not caused by low concentrations of enzyme or substrate, but rather to a change in epitope expression ofapoA-I in interstitial fluid, thus making the HDL particles poor substrates for LCAT. This particular change in epitope expression could be detected by monoclonal antibody AI-11. Recently, Banka et al. (21) showed that monoclonal antibody Al-lI could inhibit rA-I HDL activation of LCAT. Our observation confirms and extends this observation into a more physiological arena, namely interstitial fluid.
Because HDL was shown to be heterogeneous (32), we have investigated which population of interstitial HDL showed this change of epitope expression. Preliminary data suggested that a-migrating but not pre-fl-migrating HDL lack the epitope. Unfortunately, even the a-migrating HDL were shown to be heterogeneous (32) , and we currently do not know which subsets of the a-HDL lack this epitope.
The results shown in Fig. 4 suggested that there might be a correlation between the relative affinity of AI-1 binding to interstitial HDL and its ability to activate LCAT. This is similar to the results of Banka et al. (21 ) , who showed a correlation between binding of monoclonal antibodies and their degree of inhibition. Our results, however, suggested that at a certain level of relative affinity, any additional increase in affinity did not result in an increase in LCAT activation (see subjects 3 and 4 in Fig. 4) .
The change in epitope expression is probably determined by the particle size and its lipid composition. Our previous work (10) showed that interstitial fluid lipoprotein lipid composition is different from the plasma. Jonas et al. (33) have shown that by changing the molar ratio ofA-I to phospholipid, and thereby changing the rA-I HDL diameter, that they could change the rA-I HDL's ability to activate LCAT. Therefore, once a population of HDL with a change in apoA-I epitope is finally identified, a detailed analysis ofthe lipid composition of these particles should be revealing. At present, a detailed lipid analysis of human interstitial fluid HDL subpopulations is beyond the scope ofthis paper. This is because ofthe extremely small sample of interstitial fluid that we could obtain (0.3-0.6 ml), the low concentration of HDL in interstitial fluid (20-30% of plasma), and the heterogeneity of HDL subpopulations.
Through the work of Segrest et al. (34) and Pownall et al. (35) , it is generally accepted that apoA-I is not unique in its activation of LCAT. In fact, any protein, including synthetic artificial peptides, that contain an amphipathic helix could activate LCAT (35) . One consequence ofour investigation is the demonstration that a single epitope on apoA-I may be responsible for the activation of LCAT (see Fig. 5 , A and B, where preincubation of Al-11 with either rA-I HDLs or HDL inhibited LCAT activation 81 and 63%, respectively). In apoA-I, there are eight amphipathic helical 22mers and two 1 lImers. Thus, one would expect that binding of monoclonal antibody to one epitope on one helix could not inhibit LCAT activation so exclusively. One alternative explanation ofour results could be that Al-11 binding to apoA-I caused a steric hindrance that obstructed other amphipathic helixes from binding to LCAT. ApoA-I has a molecular mass of27 kD, whereas an IgG such as AI-I 1 has a molecular mass of 150 kD. This could not be the sole explanation, since AI-10 did not have as dramatic an effect as Al-I 1. Our results are consistent with the results ofAnantharamaiah et al. (36) , who proposed that peptide 66-121 is the region of apoA-I that is responsible for the majority ofbinding to and activation ofLCAT. This region, however, contained 55 amino acids consisting of two 22mers on either side of one 1 lImer. The localization of Al-Il binding to residues 96-1 1 1 would suggest that only the latter 22mer (amino acids 99-120 are the location of the second 22mer), and a small portion of the 11 mer may be important for LCAT activation.
Our measurement of LCAT activities in interstitial fluid also provide some insight into the nature of LCAT-lipoprotein interaction when it crosses the capillary endothelium. In general, plasma proteins' concentration in interstitial fluid is inversely proportional to its Stoke's radii (37) . Assuming that most proteins are globular, albumin (67 kD) had an IF/P ratio of 0.47 (Table I) , and HDL (200 kD in the form of apoA-I containing lipoproteins) had an IF/P ratio of0.24-0.36 (Table  I) . LCAT activity had an IF/P ratio of0.23. This corresponded to a molecular mass in the area of HDL. Therefore, our data (Tables I and II) suggest that LCAT crosses the capillary endothelium as a HDL-LCAT complex. This data is also consistent with the existence of an apoD apoA-I LCAT complex that has been proposed (38) .
Taking together the data from this paper and our previous work on low to nonexistent levels of lipases in the interstitial fluid ( 11 ) , our results suggest a complex series of events in the interstitial space. Immediately after crossing the interstitial space, apoA-I may change its conformation. The change could be the result of apoA-I containing HDL crossing the interstitium. It could also be caused by the interaction of HDL with peripheral cells; for example, the composition of the phospholipid in the peripheral cell membranes may be the trigger that causes this change in apoA-I epitope. This change in conformation may facilitate removal of cholesterol from the peripheral cells to HDL. In any event, the interstitial fluid HDL are poor activators and substrates for LCAT, even though LCAT is present. Upon returning to the plasma, the interstitial fluid HDL will interact with plasma HDL. This interaction may be sufficient to change the conformation of interstitial fluid apoA-I to again make it into good substrate for LCAT. The interaction with plasma HDL could be nothing more than dilution of plasma membrane phospholipids with HDL phospholipids. Alternatively, the interstitial HDL may be recognized and metabolized differently than the plasma HDL. The action of cholesteryl ester transfer protein in this sequence ofevents remains to be determined. The exact nature of this change in epitope in apoA-I also remains to be determined.
In conclusion, the LCAT activating epitope of apoA-I, as defined by monoclonal antibody Al-I1 binding, is different in the HDL of interstitial fluid than in plasma HDL.
